<i>In vivo</i> functional assessment of recombinant adeno-associated viruses carrying genes of protectively significant antigens of the African swine fever virus

Abstract

Relevance. African swine fever (ASF) is a viral hemorrhagic disease with exceptionally high mortality in members of the family Suidae, with serious economic consequences associated with production losses, trade restrictions and eradication programs. To date, no effective commercial vaccine against ASF has been developed. Of particular interest in the design of candidate vaccines are viral vectors, in particular the adenoassociated virus of the 2nd serotype (AAV2), which has successfully proven itself as a gene therapy agent. We previously reported the ability of rAAV2 to effectively deliver ASF virus genes B646L, E183L, CP530R, CP204L into porcine cells in vitro.The aim of the study was to evaluate the in vivo functionality of adenoassociated viruses of the 2nd serotype carrying genes of protectively significant antigens of the African swine fever virus.Methods. By cloning pairwise combined genes B646L-CP530R, E183L-CP204L into the pAAV-MCS vector, bicistronic constructs with the self-cleaving P2A peptide were created. Assembly of rAAV2 was accomplished by calcium phosphate transfection of AAV293 cells. After iodixanol density gradient purification, rAAV2 was administered to pigs at a dose of 3 × 1011 viral particles and humoral and cellular immunity was assessed for 180 days. The dynamics of antibody genesis were assessed by indirect ELISA, and immunophenotyping of peripheral blood T-lymphocytes was assessed by flow cytometry.Results. It was found that the developed bicistronic constructs based on rAAV2 are safe and easily tolerated by animals and cause the induction of both humoral and cellular immune responses: the formation of virus-specific antibodies was observed, which persisted until the end of the experiment, as well as increased expression of CD8+ and CD4+ lymphocytes. The AAV platform we propose is a promising tool for creating a vaccine, however, a comprehensive characterization of rAAV2 can only be compiled after assessing its protective effect.